{
    "nctId": "NCT00288249",
    "briefTitle": "Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer",
    "officialTitle": "Prospective, Multicenter, Randomized, Independent-group, Open-label Phase II Study to Investigate the Efficacy, Safety and Tolerability of 4 Regimen With 3 Doses of ZK 219477 (16 and 12 mg/m2 Body Surface Area as 3-hour Infusion or 22 mg/m2 Body Surface Area as 30-minute or 3-hour Infusion) in Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms, Breast Cancer, Metastatic",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 82,
    "primaryOutcomeMeasure": "Tumor response rate (complete or partial response according to RECIST)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Metastatic breast cancer\n* No previous treatment with taxanes, and vinca alkaloids\n* Use of highly effective birth control methods in females of child-bearing potential\n\nExclusion Criteria:\n\n* More than 2 previous chemotherapies\n* Previous participation in another trial within the last 4 weeks\n* Breast feeding\n* Active infections",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}